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RESULTS
• A total of 189 appraisals met the inclusion criteria: 49 for CADTH (80% with a favorable outcome), 59 for PBAC (61% favorable), 36 for NICE (83% favorable), and 45 for IQWiG (40% favorable) (Figure 2 ).
• The greatest proportion of submissions were for neoplasms (n=39, 59% with a favorable outcome), endocrine/ metabolic disorders (n=29, 52% favorable), infections (n=23, 96% favorable), and respiratory system disorders (n=16, 69% favorable) (Figure 3 ).
• The highest consistency between agencies was observed for infectious disease drugs (reflecting positive reactions to new highlyeffective HCV drugs).
• The most inconsistency was observed between IQWiG and the other agencies for endocrine/metabolic disease drugs (reflecting differing attitudes to indirect comparisons for new diabetes drugs: no head-to-head trials were conducted in Germany versus the standard of care and IQWiG does not generally accept indirect comparisons, unlike other agencies).
• Only five treatments were compared within the same indication across all four agencies in 2015: 1 consistently unfavorable (apremilast for psorasis), 3 consistently favorable (though with variations in the restrictions placed -all for HCV medicines), and 1 inconsistent (secukinumab for psoriasis) (Figure 4 ).
AIM
To inform future submissions, we compared acceptance rates across four HTA agencies and explored consistency between decisions, including any differences between disease areas.
CONCLUSIONS
• Acceptance rates vary considerably between HTA agencies, and divergence in decisions appears to be influenced by disease area.
• Acceptance rates for IQWiG are on average lower than for other HTA agencies, most notably for diabetes drugs, reflecting the agency's strict evidence-based medicine approach to assessments. 
